7 Most Promising Gene Editing Stocks According to Analysts

3. Tempus AI, Inc. (NASDAQ:TEM)

Price Target Upside: 42.26%

Tempus AI, Inc. (NASDAQ:TEM) stands fourth on our list among the most promising stocks.

TheFly reported on December 15 that BofA Securities analyst Michael Ryskin lowered his price target on TEM to $80 from $90 while maintaining a Neutral rating, reflecting valuation considerations after the rally.

On the same day, JPMorgan analyst Casey Woodring also reduced his price target to $80 from $85, reiterating a Neutral outlook as he assessed the company’s growth prospects against its current share price.

These target revisions came despite continued operational momentum at TEM. The company announced that ten scientific abstracts were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, which took place from December 9 to December 12, 2025. The abstracts highlighted research utilizing the company’s multimodal data platform to support cancer research and clinical insights, underscoring the business’s expanding role in precision medicine.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that applies artificial intelligence (AI) to precision medicine, focusing on genomic sequencing, diagnostic testing, and data analysis to help physicians personalize treatment decisions, especially in oncology.